Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells $19,732.75 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 425 shares of the stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $46.43, for a total transaction of $19,732.75. Following the sale, the insider owned 138,257 shares of the company’s stock, valued at approximately $6,419,272.51. This represents a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Dennis Cho also recently made the following trade(s):

• On Wednesday, February 11th, Dennis Cho sold 5,000 shares of Twist Bioscience stock. The shares were sold at an average price of $49.93, for a total value of $249,650.00.
• On Tuesday, February 3rd, Dennis Cho sold 1,099 shares of Twist Bioscience stock. The stock was sold at an average price of $46.58, for a total value of $51,191.42.
• On Monday, December 22nd, Dennis Cho sold 324 shares of Twist Bioscience stock. The stock was sold at an average price of $34.56, for a total value of $11,197.44.

Twist Bioscience Trading Up 0.7%

Shares of TWST traded up $0.32 during mid-day trading on Friday, hitting $43.34. 104,067 shares of the company’s stock traded hands, compared to its average volume of 1,341,294. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $57.88. The firm has a market capitalization of $2.66 billion, a P/E ratio of -33.86 and a beta of 2.23. The business’s 50-day moving average price is $44.72 and its 200-day moving average price is $35.06.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $103.70 million during the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The firm’s revenue for the quarter was up 16.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC boosted its position in shares of Twist Bioscience by 12.4% in the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after purchasing an additional 832,687 shares in the last quarter. Artisan Partners Limited Partnership increased its position in Twist Bioscience by 26.7% during the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock valued at $180,403,000 after buying an additional 1,349,867 shares in the last quarter. William Blair Investment Management LLC raised its stake in Twist Bioscience by 43.7% during the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock valued at $188,874,000 after buying an additional 1,812,146 shares during the last quarter. EdgePoint Investment Group Inc. boosted its holdings in Twist Bioscience by 31.7% in the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock worth $170,590,000 after acquiring an additional 1,295,672 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Twist Bioscience by 17.4% in the fourth quarter. State Street Corp now owns 3,627,818 shares of the company’s stock worth $115,074,000 after acquiring an additional 538,755 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Barclays raised their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, February 3rd. Robert W. Baird set a $50.00 target price on Twist Bioscience in a research report on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Finally, Evercore upped their price target on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and an average target price of $45.88.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.